share_log

TC BioPharm | 8-K: Current report

TC BioPharm | 8-K: Current report

TC BioPharm | 8-K：重大事件
SEC announcement ·  03/18 08:04
Moomoo AI 已提取核心信息
On March 12, 2024, TC BioPharm (Holdings) PLC, a Scotland-based biopharmaceutical company, reported the issuance of 623,750 American Depositary Shares (ADSs) representing 12,475,000 ordinary shares. This issuance was the result of the exercise of outstanding warrants that were initially issued on August 30, 2023, and disclosed in a Report of Foreign Private Issuer filed with the SEC the following day. The transaction generated gross cash proceeds of approximately £986,398 (around $1,263,000) for TC BioPharm. The ADSs were issued under the exemption from the registration requirements provided by Section 4(a)(2) of the Securities Act. The company, which is registered with the United States Securities and Exchange Commission and listed on The Nasdaq Stock Market LLC, is identified as an emerging growth company.
On March 12, 2024, TC BioPharm (Holdings) PLC, a Scotland-based biopharmaceutical company, reported the issuance of 623,750 American Depositary Shares (ADSs) representing 12,475,000 ordinary shares. This issuance was the result of the exercise of outstanding warrants that were initially issued on August 30, 2023, and disclosed in a Report of Foreign Private Issuer filed with the SEC the following day. The transaction generated gross cash proceeds of approximately £986,398 (around $1,263,000) for TC BioPharm. The ADSs were issued under the exemption from the registration requirements provided by Section 4(a)(2) of the Securities Act. The company, which is registered with the United States Securities and Exchange Commission and listed on The Nasdaq Stock Market LLC, is identified as an emerging growth company.
2024年3月12日，总部位于苏格兰的生物制药公司TC Biopharm（Holdings）PLC报告称，发行了代表12,475,000股普通股的623,750股美国存托股（ADS）。此次发行是行使未兑现的认股权证的结果，这些认股权证最初于2023年8月30日发行，并在第二天向美国证券交易委员会提交的外国私人发行人报告中进行了披露。该交易为TC BioPharm带来了约986,398英镑（约合12.63万美元）的总现金收益。美国存托凭证是在《证券法》第4（a）（2）条规定的注册要求的豁免下发行的。该公司在美国证券交易委员会注册并在纳斯达克股票市场有限责任公司上市，被认定为新兴成长型公司。
2024年3月12日，总部位于苏格兰的生物制药公司TC Biopharm（Holdings）PLC报告称，发行了代表12,475,000股普通股的623,750股美国存托股（ADS）。此次发行是行使未兑现的认股权证的结果，这些认股权证最初于2023年8月30日发行，并在第二天向美国证券交易委员会提交的外国私人发行人报告中进行了披露。该交易为TC BioPharm带来了约986,398英镑（约合12.63万美元）的总现金收益。美国存托凭证是在《证券法》第4（a）（2）条规定的注册要求的豁免下发行的。该公司在美国证券交易委员会注册并在纳斯达克股票市场有限责任公司上市，被认定为新兴成长型公司。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息